Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Rheumatoid arthritis (RA) is an inflammatory autoimmune polyarthritis affecting ∼1% of the world population, resulting in the loss of joint function and progressive structural damage in affected joints. Fexofenadine has been widely used to treat various allergic diseases, like allergic rhinitis, conjunctivitis and chronic idiopathic urticaria. the molecular mechanisms underlying fexofenadine mediated inhibition of TNF-α signalling
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Fexo group | Active Comparator |
| |
| Placepo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fexofenadine | Drug | tablet |
| |
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| ACR 20% | improvement criteria (ACR20) response rate based on the count of tender/swollen joints, | at baseline |
| ACR 20% | improvement criteria (ACR20) response rate based on the count of tender/swollen joints, | at week 12 |
| (HAQDI) | HAQ-DI (Health Assessment Score- Disability index), in which patients are asked to rate their capacity to perform 20 activities of daily living (ADL). Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). For each section the score given to that section is the worst score within the section | at baseline |
| (HAQDI) | HAQ-DI (Health Assessment Score- Disability index), in which patients are asked to rate their capacity to perform 20 activities of daily living (ADL). Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). For each section the score given to that section is the worst score within the section | at week 12 |
| CRP | the level of CRP | at baseline |
| CRP | the level of CRP | at week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| TNF-α | Serum level Tumor necrosis factor- alpha (TNF-α) | at baseline and at week 12 |
| IL6 | Serum level of IL6 | at baseline and at week 12 |
Not provided
Inclusion Criteria
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ahmed Ismaeel | Contact | 01090905827 | hoda_cp@yahoo.com | |
| Engy Wahsh | Contact | 01003095692 | engywahsh@o6u.edu.eg |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beni-Suef Hospital | Recruiting | Banī Suwayf | Egypt |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C093230 | fexofenadine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
tablet |
|
| Faculty of Medicine - Beni Suef Hospital | Recruiting | Banī Suwayf | Egypt |
|
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |